← Oncology Approval Tracker

FDA DECISION ·

Ensacove

ensartinib · Xcovery Holdings

FDA approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have not received an ALK inhibitor.

LAMPGEN ANALYSIS

Why it matters

The approval adds an oral ALK inhibitor for ALK inhibitor-naive patients. The pivotal comparison was with crizotinib.

What research teams should watch

Check ALK status and prior drug records, and plan for serial liver tests and prompt review of skin reactions.

PRIMARY RECORDS

Sources